The Martha Conlon Robeck Advocacy Program
Literature, news and videos pertinent to
The Martha Conlon Robeck Advocacy Program
- Oncology Today with Dr Neil Love— The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer with Dr Shannon Westin
- Open AccessReview— Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment
- Study Finds Patients With Rare Ovarian Cancer Develop Chemoresistance | Cancer Therapy Advisor
- FDA Approves Niraparib for Patients With Homologous Recombination Deficiency–Positive Advanced Ovarian Cancer
By The ASCO Post Staff
powered by Surfing Waves
Martha Conlon Robeck Advocacy Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
For more information about this special program, please click on...
Federal Tax I.D.: EIN 86-0818253 | WA Charities: 37195